Practical Approach to Dyslipidemia Management: Latest Guidelines for Pharmacists
As a pharmacist, you know that dyslipidemia is a major risk factor for cardiovascular diseases. Proper management is key to reducing the risk of heart attack, stroke, and other cardiovascular events. Here are some practical strategies for managing dyslipidemia in patients...
Screening all adults starting at age 19 and children aged 9 to 11 is crucial to establish baseline lipid levels and identify potential genetic disorders, such as familial hypercholesterolemia (FH). Screening with a standard lipid profile is the first step. You should emphasize the importance of early detection to prevent future cardiovascular complications. Use the Martin/Hopkins or Sampson/NIH equations to estimate LDL-C instead of the Friedewald formula. These formulas offer greater accuracy, especially when triglycerides are elevated or LDL-C is low. This is an important point to stress when interpreting lipid panels in practice.
Measuring Lipoprotein(a) [Lp(a)] at least once in all adults can be a game changer in risk assessment. High Lp(a) levels (≥125 nmol/L or ≥50 mg/dL) are linked to a 1.4-fold increased risk of atherosclerotic cardiovascular disease (ASCVD). If the levels are elevated, this should be taken into account when assessing a patient's overall cardiovascular risk.
Calculate the 10-year and 30-year ASCVD risk using the PREVENT-ASCVD equations. This tool is more reliable than the older Pooled Cohort Equations for primary prevention in adults aged 30–79. It’s important to categorize patients into one of the four risk groups:
- Low (< 3%)
- Borderline (3% to <5%)
- Intermediate (5% to <10%)
- High (≥10%)
This categorization helps in deciding whether to initiate therapy or just focus on lifestyle changes.
Engage in a clinician-patient risk discussion (CPR model). When discussing treatment options, remember to Calculate, Personalize, and Reclassify risk using a Coronary Artery Calcium (CAC) score. If the CAC score is >0 AU, consider starting therapy. If the score is ≥100 AU or in the ≥75th percentile for their age and sex, prioritize therapy.
Lifestyle modifications are the foundation of treatment. You should always recommend heart-healthy diets rich in fruits, vegetables, whole grains, and legumes, while advising patients to replace saturated fats with monounsaturated and polyunsaturated fats. 150 minutes of moderate aerobic exercise per week and resistance exercise two days per week are also key components in managing lipid levels. Weight loss of 5% to 10% can significantly improve both TG and LDL-C levels, especially in patients who are overweight or obese. Ensure patients are aware of the positive impact lifestyle changes can have on their lipid profile and overall cardiovascular health. Avoid dietary supplements such as red yeast rice, fish oil, and turmeric for lipid-lowering purposes. While they may be popular, the evidence supporting their effectiveness is inconsistent, and they have not been proven to reduce cardiovascular events significantly compared to FDA-approved therapies.
Statins are the first-line pharmacotherapy for managing dyslipidemia. High-intensity statins (e.g., Atorvastatin 40–80 mg, Rosuvastatin 20–40 mg) should be prescribed to patients with established ASCVD or those at high risk, aiming for a ≥50% reduction in LDL-C. For borderline or intermediate-risk adults, moderate-intensity statins (e.g., Atorvastatin 10–20 mg, Rosuvastatin 5–10 mg) should be prescribed for a 30%–49% reduction in LDL-C. Adjust statin doses for individuals of East Asian ancestry, as they may be more sensitive to statins, requiring lower doses to achieve optimal lipid control.
- Add-on agents should be considered if LDL-C and non-HDL-C goals aren’t met with statins alone.
- For instance, Ezetimibe (10 mg daily) can be used as the first add-on therapy, offering a 25% LDL-C reduction.
- PCSK9 inhibitors (e.g., Alirocumab 75–150 mg q2wk, Evolocumab 140 mg q2wk) are potent alternatives, providing 45% to 64% LDL-C reduction.
- For patients with statin-related muscle symptoms, consider adding Bempedoic Acid (180 mg daily) as it is effective for high-risk patients and may reduce the need for statins. Additionally, Inclisiran (284 mg SQ every 6 months) is a newer option that may be useful in high-risk patients, though more cardiovascular outcome trials are needed.
- Severe hypertriglyceridemia (TG ≥500 mg/dL) should be managed with fibrates (e.g., Fenofibrate 40–200 mg daily) or prescription omega-3 ethyl esters (4g daily) to reduce the risk of pancreatitis. If TG levels are between 150–499 mg/dL, Icosapent ethyl (2g twice daily) should be considered to reduce ASCVD risk.
Monitor lipid profiles 4 to 12 weeks after starting or adjusting therapy and then every 6 to 12 months thereafter. It’s essential to assess therapy response regularly and adjust as needed. For patients who experience muscle pain or weakness while on statins, it’s important to rule out secondary causes like hypothyroidism or intense physical activity. Creatine kinase levels should be measured if symptoms are severe. Finally, discontinue lipid-lowering therapy if life expectancy is <1 year to avoid unnecessary medication burden. Always keep patient care and quality of life in mind when prescribing long-term therapies.
References
- Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. https://doi.org/10.1161/CIR.0000000000001423.
- Siegel PM, Katzmann JL, Weinmann-Menke J, et al. A practical guide to the management of dyslipidaemia. Clin Res Cardiol. 2026;115(2):185-197.
